Shares in drinks and mixers group Fever-Tree slid by a fifth early this week, says Joanna Bourke in the Evening Standard. Founder and CEO Tim Warrillow has blamed a “subdued end to the year in the UK” for a 1% fall in UK sales and has warned that Fever-Tree’s “much vaunted” expansion into the US will suffer “slower growth than before”.
The warning has reduced the stock price to a three-year low. Fever-Tree’s market value has declined to £1.76bn, down from a peak of £4.5bn 18 months ago. While Fever-Tree’s management has attempted to cushion the blow with talk about “good momentum outside the UK” and has promised that home sales will “return to growth”, this is more than just a temporary blip, says Kate Burgess in the Financial Times. Competition from rival soft drinks firms is “hotting up” while the “craze” for gin and tonic “is turning”. What’s more, a “smallish British company” like Fever-Tree will find it harder than it thinks to break into the US market: building a brand is “challenging” and distribution is “tough”. Still, all is not lost . A buyer “with pockets deep enough to break the US” could snap it up.
Don’t be so sure, says Andrea Felsted on Bloomberg. A potential acquirer will first want to see evidence “that the company is stabilising”. After all, Fever-Tree’s attraction to shareholders come from its “fast growth”, and while 10% revenue expansion “is still much better” than the pace seen in consumer goods or food retail, it’s hardly impressive by Fever-Tree’s recent standards.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
